Oncology

Henar Hevia and Carolyn Sousa at ASCO 2024

ASCO 2024 - Henar Hevia and Carolyn Sousa

The future of cancer care is personalisation. New breakthroughs are increasingly highly targeted, with powerful results, but only for patients with particular genetic markers.

News

AZ has another setback with Truqap after failed TNBC trial

AstraZeneca’s first-in-class pan-AKT inhibitor Truqap was unable to improve overall survival (OS) in a phase 3 trial in triple-negative breast cancer (TNBC), denting the prospects of the ne

News

Study finds low secondary cancer risk with CAR-Ts

There’s no doubt that CAR-T therapies have transformed the treatment of many blood cancers, but a risk of secondary malignancies has cast a pall over the class.

News

New data at EHA backs Sanofi, Innate’s NK cell engager

One of the lead candidates in Sanofi natural killer (NK) cell engager alliance with Innate Pharma has shown encouraging and durable efficacy in various haematological cancers, according to

News

FDA widens label for BMS’ cancer drug Augtyro

Bristol-Myers Squibb has claimed FDA approval for a new, tumour-agnostic indication for Augtyro, the cancer drug it acquired as part of its $4.1 billion takeover of Turning Point Therapeuti

Oncology

Four takeaways from ASCO24

Last weekend, I travelled to Chicago for the annual conference of the American Society of Clinical Oncologists— the annual event where major breakthroughs in cancer care are announced.

ASCO 2024 - Henar Hevia and Carolyn Sousa

AZ has another setback with Truqap after failed TNBC trial

Study finds low secondary cancer risk with CAR-Ts

New data at EHA backs Sanofi, Innate’s NK cell engager

FDA widens label for BMS’ cancer drug Augtyro

Four takeaways from ASCO24

An AI supercomputer and discovering next-gen brain disorder ...

How to meet your physicians where they are online

Oncology

Editor's Picks